Vascular Endothelial Growth Factor-A (VEGF-A) Protein Archives

FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

Approvals, Bispecific Antibody, Blood Vessels, Diabetic Macular Edema, FDA/Regulatory, Genentech, Ophthalmics, Roche, Therapeutics, Vascular Endothelial Growth Factor-A (VEGF-A) Protein, Vision Loss, Wet Age-Related Macular Degeneration

The U.S. Food and Drug Administration approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).

January 28, 2022/by Business Wire

BioSpace reviews some of the more interesting recently published scientific studies, including whether the Covid-19 virus relieve pain.

October 9, 2020/by Andrew Humphreys